  of the CEO and CFO remuneration at ‘on-target performance’ for 2024 revealed the 
following positioning:
Table 8 – Market positioning of 2024 remuneration for the CEO and CFO
Benchmarks Nordic general industry European pharma
CEO Above the upper quartile Slightly below the lower quartile
CFO Above the upper quartile Slightly below the lower quartileRemuneration Report 2024 / 3. Remuneration of Executive Management 
Modou Seye lives with type 2 
diabetes in Senegal.

123.4 Executive remuneration in 2024
Table 9 below includes the total remuneration of Executive Management in 2024. 
 
Table 9 – Actual remuneration of Executive Management for 20241
DKK million Base salary Pension BenefitsShort-term 
incentive Total3Long-term 
incentive4Total Fixed Variable Total
Lars Fruergaard Jørgensen - President and CEO 18.4 1.8 0.3 12.7 33.2 23.9 57.1 20.5 36.6 57.1
Karsten Munk Knudsen - CFO 9.1 0.9 0.4 6.8 17.2 9.6 26.8 10.4 16.4 26.8
Non-registered executives271.2 14.9 9.3 57.7 153.1 74.1 227.2 9 % of max 16.7%
Total 100% 73%5
1. Sales growth in comparable exchange rates. 2. Operating profit growth in comparable exchange rates. 3. For performance within Purpose & Sustainability, and Innovation 
& Therapeutic Focus, see table 15 below. 4. For individual performance, see table 16 below. 5. The discretionary downward adjustment of the group performance by 16% is 
included in the total.Remuneration Report 2024 / 3. Remuneration of Executive Management 
Table 13 – Short-term incentive programme 2024 for the CEO
Measure Metric Weighting Min Target MaxPerformance 
2024STIP 
outcome of 
maximum 
pay-out
Commercial 
ExecutionSales growth125.0% 18.2% 22.2% 26.2% 27.0% 25.0%
Financials Operating profit 
growth225.0% 21.7% 25.7% 29.7% 28.5% 21.1%
Purpose & 
Sustainability, 
and Innovation & 
Therapeutic Focus3Achievement 
of strategic 
initiatives25.0% 7 out of 13 10 out of 13 13 out of 13 12 out of 13 20.8%
Individual 
performance4Individual 
targets25.0% Qualitative assessment 50% of max s as assessed by the 
Board at the beginning of 2025.
Furthermore, during the performance period (2022-2024) the share price increased by 87%, from DKK 334.5 
to DKK 624.2, resulting in a similar increase in the value of the long-term incentive and thereby aligning the 
interests of the shareholders and the executives.
The total number of shares to be released to the Executive Management by the end of January 2025 is 
specified in table 19 below. No dividend on the shares was paid to the executives during the three-year 
performance period. 
The executives are required to hold 50% of the shares vesting for two years (2025 and 2026). During the 
two-year holding period no further performance measures apply.Table 18 – Long-term incentive programme 2022 - final performance
Performance LTIP 
outcome of 
maximum 
pay-out Measure Metric Weighting 2022 2023 20243-year 
average Min Target Max
Commercial 
Execution3-year average 
sales growth133.3% 16.4% 35.6% 25.7% 25.9% 8.0% 10.0% 12.0% 33.3% 3.9 4.3
Change (0.4) 0.1 0.3 0.8 0.4
% change (13%) 4% 11% 26% 10%Remuneration Report 2024 / 4. Remuneration and Company Performance 2020–2024

224.2 Executive remuneration 2020–2024
A summary of the development of the remuneration of the CEO and CFO in the five-year period 2020–2024 
is provided in table 28 and table 29 below.
Table 28 - Remuneration 2020–2024 for the CEO
DKK million 2020 202122022 2023 20243% change
Base salary 14.1 16.7 17.1 17.9 18.4
Pension on base salary 3.5 1.7 1.7 1.8 1.8
Benefits 0.3 0.3 0.3 0.3 0.3
Total base salary, pension, and benefits 17.9 18.7 19.1 20.0 20.5 3%
Short-term incentive 14.2 12.6 13.2 17.2 12.7
Pension on short-term incentive 3.6 — — — —
Total short-term incentive and pension 17.8 12.6 13.2 17.2 12.7 (26%)
Long-term incentive 20.8 27.0 27.8 31.0 23.9 (23%)
Total 56.5 58.3 60.1 68.2 57.1 (16%)
Change 1.7 1.8 1.8 8.1 (11.1)
% change 3% 3% 3% 13% (16%)
% change annualised1— — — — —
1. % change in annualised pay is calculated as the difference be